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We describe an assay for methotrexate in biological fluids.
The assay is based on inhibition by methotrexate of dihydrofolatereductasefrom Lactobacillus case!. The lower limit of sensitivity in serum is 2 X 108 mol (about 10 gig) of methotrexate per liter. Within-runprecisionis ±5% (coefficient of variation) and day-to-dayvariation is18%. Advantages of the assay are ease of manipulation, high sensitivity, and specificity.
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Methotrexate
(MTX) is a folic acid antagonist widely used in cancer chemotherapy (1) (2) (3) (4) and sometimes in severe psoriasis (5) . In recent years high doses of MTX followed by citrovorum factor "rescue" have been used in treating certain tumors (6) . The citrovorum factor restores the body pools of tetrahydrofolate cofactors, which are depleted in the presence of MTX. MTX blocks the reduction of folic acid and dihydrofolic acid to tetrahydrofolic acid by inhibiting the enzyme tetrahydrofolate dehydrogenase (EC 1.5.1.3). Although it is thought that MTX damages sensitive tumors more than other rapidly proliferating tissues (1) , such selectivity is not complete, and serious toxicity-including skin rash, myelosuppression, mucosal ulceration, and renal damage-can result. Monitoring serum methotrexate to predict toxicity after high-dose MTX therapy is reported (7) (8) (9) . In addition, a correlation has been demonstrated between cerebrospinal fluid MTX concentrations and neurotoxicity after intrathecal administration of MTX (10) . Use of serum MTX values to adjust the citrovorum factor dose and avert impending toxicity has also been reported
The enzyme-inhibition assay for MTX has been available for over a decade (11, 12) and has been used in studies of the pharmacology of MTX (1, 8, 9, 13 The resulting suspension was stirred while 0.3 ml was withdrawn and dissolved in 2.7 ml of the dihydrofolate buffer. When 20 il of this solution was added to 1.0 ml of reaction buffer, the absorbance in the 1-cm pathlength cell of the spectrophotometer was 0.075 ± 5 A. (If necessary, the concentration of the suspension was adjusted to bring the absorbance into the proper range.) The suspension was stored in 0.3-ml aliquots in plastic culture tubes. Stored capped and frozen at -20 #{176}C in the dark, this preparation is stable for at least two months.
Dihydrofolate
solution.
An aliquot of dihydrofolic acid forthe assay was prepared each day by thawing a tube of the suspension and diluting it with 2.7 ml of the dihydrofolate buffer. The resulting solution was then loaded into the 1.0-mi Hamilton Dispenser. Both the filled dispenser and the tube containing the unused dihydrofolic acid solution were stored in crushed ice.
The dispenser was refilled from the tube as needed, and the unused portion was discarded at the end of the day. were used. Serum specimens were stable for at least six months when stored frozen at -20 #{176}C, but only for three days at room temperature.
Procedure
A set of calibrators and a methotrexate control sample were thawed in a beaker of water at room temperature. The reaction mixture and dihydrofolate solution were prepared as above. Twenty microliters of a calibrator was pipetted with an Eppendorf pipet or a suitable dilutor into a 12 X 75 mm disposable glass culture tube. One milliliter of the reaction mixture was then added. The spectrophotometer cuvet was rinsed with distilled water, then purged with air for 5 s. Dihydrofolate solution, 20 ,zl, was dispensed into the reaction tube from the Hamilton Dispenser. The tube was then vortex-mixed briefly (1-2 s) and the entire solution was aspirated into the cuvet of the spectrophotometer. This aspiration automatically started the timer and, after a delay of 20 s, the initial absorbance was printed. The change in absorbance (.A) was printed 120 s later. The five calibrators were each assayed opce, and a "zero calibrator" of distilled water was included. The values of z.A were plotted vs. the methotrexate concentration ( Figure 1 ) to obtain a calibration curve. Patients' samples (serum or cerebrospinal fluid), and the methotrexate control were assayed in the same way. Serial tenfold dilutions with water were made to obtain a value which fell within the range of the calibrators. § 2.58 X 10-6 2.49 X iO-3 3.47 X iO-7 Results for patient samples were checked by making a further dilution with water to obtain another value of #{163}4 for each sample that fell within the range of the calibrators. A separate calibration curve was run with each batch of reaction mixture and dihydrofolic acid. A control containing 5.0 X i0 mol of MTX per liter of plasma was diluted 10-fold and assayed daily.
A calibration curve was stable for 12 h. Individual patient's samples could be analyzed in about 5 mm, once the calibration curve was established.
Results
The assay measures MTX in concentrations of 2.0 X 10_8 to 3.0 X iO mol/liter. Samples were diluted in 10-fold steps with water to obtain a concentration in this range. Serum samples were obtained from 50 hospitalized patients receiving various drugs other than MTX. Included were icteric, lipemic, and hemolyzed specimens. Each sample gave the expected result when an- In existing enzymatic methods, the stability and availability of reagents has been a serious problem. These difficulties have precluded its use as a routine, fast, analytical method. The method described in this paper suffers from none of the above limitations.
It is sensitive, precise, accurate, and specific. It uses a common clinical laboratory instrument and commercially available reagents. Details are given for the manipulation and storage of reagents. We believe that this method can be adopted by most clinical chemistry laboratories and that it is a vital adjunct to MTX therapy.
